Home>R&D>Milestones

Milestones

12-2018 In 2018, Fosun Pharma has completed 9 generic drug consistency evaluation projects in mainland China.
11-2018 In November 2018, FCN-159 tablet, a new drug of a subsidiary of Fosun Pharma, was approved by the State Food and Drug Administration for clinical trials of advanced solid tumors.
08-2018 In August 2018, SPAQ-CO?Disp, a malaria prevention drug for children of Fosun Pharma, was pre-certified by the World Health Organization.
08-2018 In August 2018, the clinical test IND was launched for CAR-T cell therapy product FKC876 of Fosun Kite (trade name in the U.S. is Yescarta) in China.
01-2018 In January 2018, the HLX01 (rituximab injection) of Shanghai Henlius was included in the registration application list for drugs to be included in the priority review process (it was approved for marketing at the beginning of 2019, becoming the first biosimilar drug in China).
12-2017
10-2017
09-2017
12-2016
10-2016
10-2016
07-2015
06-2015
04-2015
12-2014 Fosun Pharma’s subsidiary Dongting Pharma obtained production license and a new drug certificate of escitalopram oxalate citalopram and tablets for treatment of depression, which is new products of category 3.1
12-2014 “Fosun Pharma 2020 Research and Innovation Plan” was issued at Fosun Pharma’s 20th anniversary celebration, the company would establish a Shanghai-centered global innovation R&D system, and strive to become a pharmaceutical enterprise with global R&D innovation capability
11-2014 Fosun Pharma’s subsidiary Shanghai Henlius submitted clinical application of monoclonal antibody agent Erbitux Biosimilar (for treating colorectal cancer) for registration
10-2014 the 11th joint packaging tablet of amodiaquine quinoline + compound sulfanilamide sheen (150 mg 25mg/500mg) (WHO reference number MA098) of Fosun Pharma’s subsidiary Guilin Pharma formally passed WHO-PQ certification
06-2014 “Industrial technology innovation strategic alliance of Fosun Pharma”,which is one of the “Industry-university-research Alliance” in National Science and Technology Major Project of the Ministry of Science and Technology of China successfully passed the acceptance
05-2014 artemether APIs passed the WHO PQ certification, creating the precedent for Guilin Pharma API PQ certification
05-2014 Fosun Pharma’s subsidiary Shanghai Henlius submitted clinical application of monoclonal antibody agent Herceptin Biosimilar (for treating gastric cancer) for registration
04-2014 Fosun Pharma obtained the exclusive license from Global TB Alliance for PA-824 drug
03-2014 Fosun Pharma’s subsidiary Shanghai Henlius obtained a clinical trial approval for rituximab Biosimilar for treating lymphoma
02-2014 Fosun Pharma won the Award for Science and Technology Innovation Enterprise of All-China Federation of Industry & Commerce
01-2014 Fosun Pharma’s subsidiary Chongqing Pharmaceutical Industry Research Institute obtained the first clinical trial approval for loxoprofen sodium gel for rheumatism and arthritis in China
11-2013 Fosun Pharma was identified as the first batch of national intellectual property advantage enterprises
10-2013 Fosun Pharma’s subsidiary Fochon Pharma signed a cooperation agreement with SELLAS Clinicals Holding AG on new drug development and licensing in Greece
10-2013 Fosun Pharma and Shanghai University of Traditional Chinese Medicine signed the cooperation agreement to establish a new Industry-university-research Alliance.
09-2013
08-2013
06-2013
03-2013
02-2013
01-2013
12-2012
12-2012
11-2012
11-2012
11-2012
07-2012
05-2012
09-2011
01-2011
11-2010
04-2010
02-2010
03-2009
12-2008
01-2008
08-2007
07-2006
05-2006
03-2006
12-2005
10-2005
10-2005
08-2003
01-2003
07-2002
06-2002
12-2001
09-2001
11-2000
12-1999
10-1999
12-1998
12-1998
11-1998
08-1998
01-1998
01-1998